The year 2017 in cardiology: aorta and peripheral circulation

Cost-effectiveness analysis: A tool in the hands of the clinician

“…In fact, although often neglected by physicians, PAD represents a vast public health burden with more than 35 m people in Europe, as compared to about 29 m people suffering from ischaemic heart disease. 7 In order to improve the healthcare of PAD patients we need not only effective treatments but also to increase the awareness and knowledge of PAD among cardiologists, as stated in the mission of the Working Group on Aorta and Peripheral Vascular Diseases of the European Society of Cardiology which I had the honour to chair. 8 In this context, I was particularly interested in the study entitled 'Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral artery disease: An Australian healthcare perspective', published in this issue of the European Journal of Preventive Cardiology.…”